InvestorsHub Logo
Followers 14
Posts 827
Boards Moderated 0
Alias Born 06/26/2014

Re: None

Saturday, 01/07/2023 1:35:16 AM

Saturday, January 07, 2023 1:35:16 AM

Post# of 477665
Next week’s PR should read:

Anavex’s Blarcamesime data is superior to the controversial newly approved Lecanemab. And a much better safety profile.

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent AVXL News